Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice

We have developed monoclonal antibodies directed against the pseudopeptide ?-130, derived from the highly conserved malarial antigen Plasmodium falciparum merozoite surface protein 2 (MSP-2), for obtaining novel molecular tools with potential applications in the control of malaria. Following isotype switching, these antibodies were tested for their ability to suppress blood-stage parasitemia through passive immunization in malaria-infected mice. Some proved totally effective in suppressing a lethal blood-stage challenge infection and others reduced malarial parasitemia. Protection against P. berghei malaria following Ig passive immunization can be associated with specific immunoglobulins induced by a site-directed designed MSP-2 reduced amide pseudopeptide. © 2008 Elsevier Inc. All rights reserved.

• Fecha de publicación: 2009
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/22784
• Acceso en línea: https://doi.org/10.1016/j.peptides.2008.10.022; https://repository.urosario.edu.co/handle/10336/22784
• Palabra clave: Immunoglobulin; Immunoglobulin class; Malaria vaccine; Merozoite surface protein 2; Monoclonal antibody; Monoclonal antibody anti pseudopeptide psi 130; Pseudopeptide; Unclassified drug; Animal cell; Animal experiment; Animal model; Animal tissue; Article; Controlled study; Drug design; Drug mechanism; Drug synthesis; Female; Mouse; Nonhuman; Parasitemia; Passive immunization; Plasmodium berghei infection; Plasmodium falciparum; Priority journal; Animals; Antibodies, protozoan; Antigens, protozoan; Disease models, animal; Female; Immunization, passive; Malaria; Mice; Mice, inbred balb c; Parasitemia; Plasmodium berghei; Plasmodium falciparum; Protozoan proteins; Recombinant proteins; Murinae; Mus; Plasmodium berghei; Plasmodium falciparum; Anti-malarial vaccine; Ig isotype; In vivo neutralizing activity; Murine malarial infection; Pseudopeptide; protozoan
• License: Abierto (Texto Completo)